Rahman TM, Hodgson HJ. Review article: liver support systems in acute hepatic failure. Aliment Pharmacol Ther.1999;13:1255-1272.
Riordan SM, Williams R. Extracorporeal support and hepatocyte transplantation in acute liver
failure and cirrhosis. J Gastroenterol Hepatol.1999;14:757-770.
Lee WM. Acute liver failure. N Engl J Med.1993;329:1862-1872.
Tandon BN, Bernauau J, O'Grady J.
et al. Recommendations of the International Association for the Study of the
Liver Subcommittee on nomenclature of acute and subacute liver failure. J Gastroenterol Hepatol.1999;14:403-404.
Sorkine P, Ben Abraham R, Szold O.
et al. Role of the molecular adsorbent recycling system (MARS) in the treatment
of patients with acute exacerbation of chronic liver failure. Crit Care Med.2001;29:1332-1336.
Russell PS. Understanding resource use in liver transplantation. JAMA.1999;281:1431-1432.
Allen JW, Hassanein T, Bhatia SN. Advances in bioartificial liver devices. Hepatology.2001;34:447-455.
Bonn D. Hybrid devices offer hope for the failing liver. Lancet.1996;348:1372.
Wilkinson AH, Ash SR, Niessenson AR. Hemodiabsorption in treatment of hepatic failure. J Transpl Coord.1998;8:43-50.
Mitzner SR, Stange J, Klammt S.
et al. Improvement of hepatorenal syndrome with extracorporeal albumin dialysis
MARS: results of a prospective, randomized, controlled clinical trial. Liver Transpl.2000;6:277-286.
Ellis AJ, Hughes RD, Wendon JA.
et al. Pilot-controlled trial of the extracorporeal liver assist device in
acute liver failure. Hepatology.1996;24:1446-1451.
Stevens C, Busuttil RW, Han S.
et al. An interim analysis of a phase II/III prospective randomized multicenter
controlled trial of the HepatAssist Bioartificial Liver Support System for
the treatment of fulminant hepatic failure [abstract]. Hepatology.2001;34:299A.
Benson K, Hartz AJ. A comparison of observational studies and randomized, controlled trials. N Engl J Med.2000;342:1878-1886.
Concato J, Shah N, Horwitz RI. Randomized, controlled trials, observational studies, and the hierarchy
of research designs. N Engl J Med.2000;342:1887-1892.
Liu JP, Kjaergard LL, Als-Nielsen B, Gluud C. Artificial and bioartificial support systems for acute and acute-on-chronic
liver failure (Cochrane Hepato-Biliary Group Protocol) [Cochrane Review on
CD-ROM]. Oxford, England: Cochrane Library, Update Software; 2002; issue 2.
Liu JP, Kjaergard LL, Als-Nielsen B, Gluud C. Artificial and bioartificial support systems for liver failure: a Cochrane
Hepato-Biliary Group Protocol. Liver.2002;22:433-438.
International Conference on Harmonisation Expert Working Group. Code of Federal Regulations and International Conference
on Harmonization Guidelines. Philadelphia, Pa: Parexel Barnett; 1997.
Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias: dimensions of methodological quality associated
with estimates of treatment effects in controlled trials. JAMA.1995;273:408-412.
Moher D, Pham B, Jones A.
et al. Does quality of reports of randomised trials affect estimates of intervention
efficacy reported in meta-analyses? Lancet.1998;352:609-613.
Kjaergard LL, Villumsen J, Gluud C. Reported methodologic quality and discrepancies between large and small
randomized trials in meta-analyses. Ann Intern Med.2001;135:982-989.
Egger M, Davey SG, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ.1997;315:629-634.
Redeker AG, Yamahori HS. Controlled trial of exchange-transfusion therapy in fulminant hepatitis. Lancet.1973;1:3-6.
Gazzard BG, Portmann B, Weston MJ.
et al. Charcoal hemoperfusion in the treatment of fulminant hepatic failure. Lancet.1974;1:1301-1307.
Silk DB, Williams R. Experiences in the treatment of fulminant hepatic failure by conservative
therapy, charcoal haemoperfusion, and polyacrylonitrile haemodialysis. Int J Artif Organs.1978;1:29-33.
Denis J, Opolon P, Nusinovici V.
et al. Treatment of encephalopathy during fulminant hepatic failure by haemodialysis
with high permeability membrane. Gut.1978;19:787-793.
Gimson AES, Braude S, Mellon PJ.
et al. Earlier charcoal hemoperfusion in fulminant hepatic failure. Lancet.1982;2:681-683.
Margulis MS, Erukhlmov EA, Andreiman LA, Viksna LM. Temporary organ substitution by hemoperfusion through suspension of
active donor hepatocytes in a total complex of intensive therapy in patients
with acute hepatic insufficiency. Resuscitation.1989;18:85-94.
Bion JF, Bowden MI, Chow B.
et al. Atracurium infusions in patients with fulminant hepatic failure awaiting
liver transplantation. Intensive Care Med.1993;19:S94-S98.
Li LJ, Huang JR, Chen JH.
et al. The study of treatment of hepatitis gravis by artificial liver support
system. Chin J Hepatol.1997;5:202-203.
Jiang YS, Chen YM, Yao JL.
et al. Evaluation of the therapeutic effect of artificial liver support system
on severe viral hepatitis. Chin J Intern Med.2000;39:115-117.
O'Grady JG, Gimson AE, O'Brien CJ.
et al. Controlled trials of charcoal hemoperfusion and prognostic factors
in fulminant hepatic failure. Gastroenterology.1988;94:1186-1192.
Hughes RD, Pucknell A, Routley D.
et al. Evaluation of the BioLogic-DT sorbent-suspension dialyser in patients
with fulminant hepatic failure. Int J Artif Organs.1994;17:657-662.
Mazariegos GV, Ash SR, Patzer JF. Preliminary results: randomized clinical trial of the BioLogic-DT in
treatment of acute hepatic failure (AHF) with coma [abstract]. Artif Organs.1997;21:529.
Kramer L, Gendo A, Madl C.
et al. A controlled study of the BioLogic-DT System in chronic hepatic encephalopathy
Ellis AJ, Hughes RD, Nicholl D.
et al. Temporary extracorporeal liver support for severe acute alcoholic hepatitis
using the BioLogic-DT. Int J Artif Organs.1999;22:27-34.
Mitzner SR, Stange J, Klammt S.
et al. Extracorporeal detoxification using the molecular adsorbent recirculating
system for critically ill patients with liver failure. J Am Soc Nephrol.2001;12(suppl 17):S75-S82.
He JQ, Chen CY, Deng JT.
et al. Clinical study on the treatment of fatal hepatitis with artificial
liver support system. Chin Crit Care Med.2000;12:105-108.
Heemann U, Treichel U, Loock J.
et al. Albumin dialysis in cirrhosis with superimposed acute liver injury:
a prospective, controlled study. Hepatology.2002;36:949-958.
Pocock SJ, Hughes MD, Lee RJ. Statistical problems in the reporting of clinical trials: a survey
of three medical journals. N Engl J Med.1987;317:426-432.
Peto R, Pike MC, Armitage P.
et al. Design and analysis of randomized clinical trials requiring prolonged
observation of each patient, I: introduction and design. Br J Cancer.1976;34:585-612.
O'Brien PC, Flemming TR. A multiple testing procedure for clinical trials. Biometrics.1979;35:549-556.
Pocock SJ. Statistical and ethical issues in monitoring clinical trials. Stat Med.1993;12:1459-1469.
Kunz R, Vist G, Oxman AD. Randomization to protect against selection bias in healthcare trials
[Cochrane Review on CD-ROM]. Oxford, England: Cochrane Library, Update Software; 2002; issue 4.